Otsuka and R-Pharm announce licensing agreement to commercialize Deltyba™ in Russia and CIS countries

Otsuka Pharmaceutical Co. Ltd. (Otsuka) and the Russian pharmaceutical company R-Pharm JSC (R-Pharm) have entered into a licensing agreement to manufacture and commercialize Deltyba™ (delamanid) for the treatment of adults with pulmonary multidrug-resistant tuberculosis (MDR-TB) in the Russian Federation and the Commonwealth of Independent States (CIS).